miR-146a suppresses the expression of vascular endothelial growth factor and inflammatory responses in diabetic retinopathy

References

• Abo-Elmatty, D. M., and E. T. Mehanna. 2019. “MIR146A rs2910164 (G/C) Polymorphism Is Associated with Incidence of Preeclampsia in Gestational Diabetes Patients.” Biochemical Genetics 57 (2): 222–233. doi:10.1007/s10528-018-9886-1.
   PubMed Web of Science ®Google Scholar
• Alexander, R. Wayne. 1994. Inflammation and Coronary Artery Disease. Massachusetts Medical Society.
   Google Scholar
• Aliseda Pérez de Madrid, D., and I. Berástegui. 2008. “Diabetic Retinopathy.” An Sist Sanit Navar 31 (Suppl 3): 23–34.
   PubMedGoogle Scholar
• Bernardo, B. C., J. Y. Ooi, R. C. Lin, and J. R. McMullen. 2015. “miRNA Therapeutics: A New Class of Drugs with Potential Therapeutic Applications in the Heart.” Future Medicinal Chemistry 7 (13): 1771–1792. doi:10.4155/fmc.15.107.
   PubMed Web of Science ®Google Scholar
• Boulton, M., D. Foreman, G. Williams, and D. McLeod. 1998. “VEGF Localisation in Diabetic Retinopathy.” The British Journal of Ophthalmology 82 (5): 561–568. doi:10.1136/bjo.82.5.561.
   PubMed Web of Science ®Google Scholar
• Cheung, N., P. Mitchell, and T. Y. Wong. 2010. “Diabetic Retinopathy.” Lancet 376 (9735): 124–136. doi:10.1016/S0140-6736(09)62124-3.
   PubMed Web of Science ®Google Scholar
• Ciccacci, Cinzia, Roberto Morganti, Davide Di Fusco, Cinzia D’Amato, Laura Cacciotti, Carla Greco, Sara Rufini, et al. 2014. “Common Polymorphisms in MIR146a, MIR128a and MIR27a Genes Contribute to Neuropathy Susceptibility in Type 2 Diabetes.” Acta Diabetologica 51 (4): 663–671. doi:10.1007/s00592-014-0582-2.
   PubMed Web of Science ®Google Scholar
• Coussens, Lisa M., and Zena Werb. 2002. “Inflammation and Cancer.” Nature 420 (6917): 860–867. doi:10.1038/nature01322.
   PubMed Web of Science ®Google Scholar
• Dong, Z., C. Yu, K. Rezhiya, A. Gulijiahan, and X. Wang. 2019. “Downregulation of miR-146a Promotes Tumorigenesis of Cervical Cancer Stem Cells via VEGF/CDC42/PAK1 Signaling Pathway.” Artificial Cells, Nanomedicine, and Biotechnology 47 (1): 3711–3719. doi:10.1080/21691401.2019.1664560.
   PubMed Web of Science ®Google Scholar
• Dunn, K. C., A. E. Aotaki-Keen, F. R. Putkey, and L. M. Hjelmeland. 1996. “ARPE-19, a Human Retinal Pigment Epithelial Cell Line with Differentiated Properties.” Experimental Eye Research 62 (2): 155–169. doi:10.1006/exer.1996.0020.
   PubMed Web of Science ®Google Scholar
• Ebneter, A., and M. S. Zinkernagel. 2016. “Novelties in Diabetic Retinopathy.” Endocrine Development 31: 84–96. doi:10.1159/000439391.
   PubMedGoogle Scholar
• Fang, Y., S. Chen, Z. Liu, W. Ai, X. He, L. Wang, P. Xie, B. Jiang, and H. Fang. 2018. “Endothelial Stem Cells Attenuate Cardiac Apoptosis via Downregulating Cardiac microRNA-146a in a Rat Model of Coronary Heart Disease.” Experimental and Therapeutic Medicine 16 (5): 4246–4252. doi:10.3892/etm.2018.6702.
   PubMed Web of Science ®Google Scholar
• Hansson, Göran K. 2005. “Inflammation, Atherosclerosis, and Coronary Artery Disease.” The New England Journal of Medicine 352 (16): 1685–1695. doi:10.1056/NEJMra043430.
   PubMed Web of Science ®Google Scholar
• Heng, L. Z., O. Comyn, T. Peto, C. Tadros, E. Ng, S. Sivaprasad, and P. G. Hykin. 2013. “Diabetic Retinopathy: Pathogenesis, Clinical Grading, Management and Future Developments.” Diabetic Medicine: A Journal of the British Diabetic Association 30 (6): 640–650. doi:10.1111/dme.12089.
   PubMed Web of Science ®Google Scholar
• Kogo, Ryunosuke, Koshi Mimori, Fumiaki Tanaka, Shizuo Komune, and Masaki Mori. 2011. “Clinical Significance of miR-146a in Gastric Cancer Cases.” Clinical Cancer Research 17 (13): 4277–4284. doi:10.1158/1078-0432.CCR-10-2866.
   PubMed Web of Science ®Google Scholar
• Labbaye, Catherine, and Ugo Testa. 2012. “The Emerging Role of MIR-146A in the Control of Hematopoiesis, Immune Function and Cancer.” Journal of Hematology & Oncology 5 (1): 1–10. doi:10.1186/1756-8722-5-13.
   PubMedGoogle Scholar
• Li, Yiwei, Timothy G. VandenBoom, Zhiwei Wang, Dejuan Kong, Shadan Ali, Philip A. Philip, and Fazlul H. Sarkar. 2010. “miR-146a Suppresses Invasion of Pancreatic Cancer Cells.” Cancer Research 70 (4): 1486–1495. doi:10.1158/0008-5472.CAN-09-2792.
   PubMed Web of Science ®Google Scholar
• Libby, Peter. 2006. “Inflammation and Cardiovascular Disease Mechanisms.” The American Journal of Clinical Nutrition 83 (2): 456S–460S. doi:10.1093/ajcn/83.2.456S.
   PubMed Web of Science ®Google Scholar
• Lightman, S., and H. M. Towler. 2003. “Diabetic Retinopathy.” Clinical Cornerstone 5 (2): 12–21. doi:10.1016/S1098-3597(03)90015-9.
   PubMedGoogle Scholar
• Liu, Z., H. Luo, L. Zhang, Y. Huang, B. Liu, K. Ma, J. Feng, et al. 2012. “Hyperhomocysteinemia Exaggerates Adventitial Inflammation and Angiotensin II-Induced Abdominal Aortic Aneurysm in Mice.” Circulation Research 111 (10): 1261–1273. doi:10.1161/CIRCRESAHA.112.270520.
   PubMed Web of Science ®Google Scholar
• Martinez, B., and P. V. Peplow. 2019. “MicroRNAs as Biomarkers of Diabetic Retinopathy and Disease Progression.” Neural Regeneration Research 14 (11): 1858–1869. doi:10.4103/1673-5374.259602.
   PubMed Web of Science ®Google Scholar
• Moreno, A., M. Lozano, and P. Salinas. 2013. “Diabetic Retinopathy.” Nutricion Hospitalaria 28 Suppl 2: 53–56. doi:10.3305/nh.2013.28.sup2.6714.
   PubMed Web of Science ®Google Scholar
• Nicholson, B. P., and A. P. Schachat. 2010. “A Review of Clinical Trials of Anti-VEGF Agents for Diabetic Retinopathy.” Graefe's Archive for Clinical and Experimental Ophthalmology 248 (7): 915–930. doi:10.1007/s00417-010-1315-z.
   PubMed Web of Science ®Google Scholar
• Platania, C. B. M., R. Maisto, M. C. Trotta, M. D'Amico, S. Rossi, C. Gesualdo, G. D'Amico, et al. 2019. “Retinal and Circulating miRNA Expression Patterns in Diabetic Retinopathy: An In Silico and In Vivo Approach.” British Journal of Pharmacology 176 (13): 2179–2194. doi:10.1111/bph.14665.
   PubMed Web of Science ®Google Scholar
• Seo, H. H., S. Y. Lee, C. Y. Lee, R. Kim, P. Kim, S. Oh, H. Lee, et al. 2017. “Exogenous miRNA-146a Enhances the Therapeutic Efficacy of Human Mesenchymal Stem Cells by Increasing Vascular Endothelial Growth Factor Secretion in the Ischemia/Reperfusion-Injured Heart.” Journal of Vascular Research 54 (2): 100–108. doi:10.1159/000461596.
   PubMed Web of Science ®Google Scholar
• Simó, R., and C. Hernández. 2008. “Intravitreous anti-VEGF for Diabetic Retinopathy: hopes and Fears for a New Therapeutic Strategy.” Diabetologia 51 (9): 1574–1580. doi:10.1007/s00125-008-0989-9.
   PubMed Web of Science ®Google Scholar
• Tiwari, A., B. Mukherjee, and M. Dixit. 2018. “MicroRNA Key to Angiogenesis Regulation: MiRNA Biology and Therapy.” Current Cancer Drug Targets 18 (3): 266–277. doi:10.2174/1568009617666170630142725.
   PubMed Web of Science ®Google Scholar
• Yang, Y., Y. Liu, Y. Li, Z. Chen, Y. Xiong, T. Zhou, W. Tao, et al. 2020. “MicroRNA-15b Targets VEGF and Inhibits Angiogenesis in Proliferative Diabetic Retinopathy.” The Journal of Clinical Endocrinology & Metabolism 105 (11): 3404–3415. doi:10.1210/clinem/dgaa538.
   PubMed Web of Science ®Google Scholar
• Zhang, D., F. L. Lv, and G. H. Wang. 2018. “Effects of HIF-1α on Diabetic Retinopathy Angiogenesis and VEGF Expression.” European Review for Medical and Pharmacological Sciences 22 (16): 5071–5076. doi:10.26355/eurrev_201808_15699.
   PubMed Web of Science ®Google Scholar